

THE UNIVERSITY of EDINBURGH

Edinburgh Research Explorer

Synthesis of Next Generation Maleimide Radical Labels

Citation for published version:

Hajjaj, B, Shah, A, Shirran, SL, Botting, CH, Slawin, AMZ, Hulme, AN & Lovett, JE 2016, 'Synthesis of Next Generation Maleimide Radical Labels' Synlett, vol. 27, no. 16, pp. 2357-2361. DOI: 10.1055/s-0035-1562451

Digital Object Identifier (DOI):

10.1055/s-0035-1562451

Link: Link to publication record in Edinburgh Research Explorer

Document Version: Peer reviewed version

Published In: Synlett

General rights

Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer content complies with UK legislation. If you believe that the public display of this file breaches copyright please contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and investigate your claim.



Synthesis of Next Generation Maleimide Radical Labels

Bouchra Hajjaj^{a,b,1} Anokhi Shah^{a,b} Stacey Bell^{a,b,2} Sally L. Shirran^b Catherine H. Botting^{b,c} Alexandra M. Z. Slawin^c Alison N. Hulme^d Janet E. Lovett*^{a,b}

^a SUPA School of Physics and Astronomy, University of St Andrews, St Andrews, KY16 9SS.

^b BSRC, University of St Andrews, St Andrews, KY16 9ST.

^c EaStChem School of Chemistry, University of St Andrews, St Andrews, KY16 9ST.

^d EaStChem School of Chemistry, University of Edinburgh, David Brewster Road, Edinburgh, EH9 3FJ.

* indicates the main/corresponding author.

jel20@st-andrews.ac.uk



Received: Accepted: Published onli

Abstract The synthesis and characterization of four new nitroxide-radical containing next generation maleimides are presented. Each new label has a single leaving group which is either a phenoxyl or bromide. The linker between the maleimide and the nitroxide-containing framework is either a racemic mixture of a short chain or an achiral longer chain. These molecules have been designed to site-specifically label vicinal cysteines in proteins for magnetic resonance studies. The characterization of the final products includes crystallography and the labeling of Sperm Whale Myoglobin protein.

Key words Next generation maleimide, succinimide, nitroxide spin label, radical, EPR spectroscopy, PRE NMR, cysteine labeling, site directed spin labeling.

Spin labels are small molecules that attach to larger molecules of interest and that stabilize a free radical. The spin labels are most likely to be used to report on their microenvironment, accessibility, motional dynamics or to enable nanometre-scale distance measurements by electron paramagnetic resonance (EPR) spectroscopy.³ Alternatively, they may be used as paramagnetic relaxation enhancing reagents in nuclear magnetic resonance (NMR) spectroscopy.⁴ It is therefore often desirable to have a spin label that demonstrates little conformational freedom while having enough flexibility to avoid disruption of the protein fold.

Commonly these labels stabilize a nitroxyl radical as part of a 5 or 6 membered carbon framework and are hence called nitroxide spin labels. These are functionalized to react at the site of interest. For proteins this site is often the thiol of cysteine. The labels can be made to covalently attach reversibly or irreversibly with short or long linkers. Attachment chemistries



Scheme 1 Proposed method for labeling proteins containing multiple free cysteines but with only one vicinal pair using a next generation maleimide. The maleimide and succinimide linkages are shown. In this work R is the nitroxide-containing framework (pyrrolinoxyl or pyrrolidinoxyl) and X a Br or OPh leaving group. The NGM labels made are shown as 1, 2, 3 and 4.



Scheme 2 Reagents and conditions: (a) Ethyl chloroformate, Et_3N , toluene, quantitative; (b) NaBH₄, EtOH, 83%; (c) TsCl, Et_3N , DCM, 67%; (d) NH₃, MeOH, 80%; (e) Bromomaleic anhydride (1 equiv.), AcOH, 47%; (f) phenol (15 equiv), t-BuOK (1.2 equiv.), dioxane, 92%.

utilize iodocetamides and maleimides to give carbon-sulfur bonds, and thiosulfonates which result in disulfide linked reagents. 5

Proteins which are excreted from the biological cell rarely contain cysteines suitable for labeling. Therefore cysteines can be engineered into sites of interest in proteins and labeled using site directed spin labeling (SDSL).³ However many excreted proteins contain disulfide bonds, where two cysteines are close in space rather than necessarily sequence, and intracellular proteins contain cysteines much more frequently.6 These situations are not ideal for designing SDSL experiments. One method to overcome this problem is to incorporate unnatural amino acids into the protein sequence. These have bioorthogonal reactivities and can therefore undergo selective labeling, alternatively there is a published example of a nitroxyl radical being incorporated directly.^{3,7} This field is progressing but at the moment the technology cannot be readily applied to any protein, and the spin labels are on long flexible linkers which is a disadvantage for many applications.



Scheme 3 *Reagents and conditions:* (a) Bromomaleic anhydride (1 equiv.), ether, 87%; (b) NaOAc (1 equiv.), Ac₂O, 64%; (c) phenol (15 equiv), *t*-BuOK (1.2 equiv.), dioxane, 92%.

Here we report on the synthesis of spin labels based on next generation maleimides.⁸ Following literature precedence, these should bind to pairs of cysteines which are close in space ("vicinal") via a succinimide bridge but bind to single cysteines with a sulfur-maleimide bond which can be reversed, see

Scheme 1. The labels proposed here are different to the existing next generation maleimide spin labels, TPMP and TPM_CP proposed by Baker and co-workers as spinostic reagents.⁹ In that work they did not use succinimide bridging but instead had two leaving groups to result in a maleimide bridged product. Here we wish to create spin labels that will give a different chemical reactivity, depending on whether single or pairs of cysteines are bound, to enable selective labeling of only pairs of cysteines (Scheme 1).



Figure 1 Ball and stick representation of compounds 1 - 4 from X-ray crystallography. The hydrogen atoms are omitted for clarity except for the stereocentre at C3' for **3** and **4**. For **3** this representation is from one of three crystallographically independent molecules.

Next generation maleimides have a leaving group and this can be altered to tune for desired properties. It has previously been shown that bromide may leave so rapidly that adjacent pairs of cysteines will each bind a maleimide marker whereas an *O*phenyl leaves less efficiently, thus favouring the intramolecular reaction and formation of a succinimide bridged product.¹⁰ We have therefore made each label type with Br (**1** and **3**) and OPh (**2** and **4**) leaving groups on the maleimide. The two families consist of either a pyrrolinoxyl (**1** and **2**) or pyrrolidinoxyl (**3** and **4**) carbon framework stabilizing the radical. The pyrrolidinoxyl has an extra stereocentre but one less carbon in the linker between the nitroxide ring and the nitrogen of the maleimide. An advantage of the pyrrolinoxyl ring is that it is expected to have greater stabilizing properties for the nitroxyl radical.



Figure 2 LC-MS spectra showing intact mass of the sperm whale myoglobin S3C (initiator Met present and counted as residue 0). Protein samples were analysed on a Waters 2795 HPLC and LCT, which had been calibrated with horse heart myoglobin, desalting with a Waters MassPrep on-line desalting cartridge, eluting with an increasing gradient of acetonitrile. The envelope of multiply charged signals was deconvoluted using MaxEnt1 software to give the molecular mass of the protein: A) Unlabeled, expected mass 18371.2, found 18372; B) with **2**, following loss of Br⁻ expected mass 18600.5, found 18608.

Carboxylic acid¹¹ 5 (Scheme 2) was converted into alcohol 7 via the intermediate mixed anhydride 6. This route was favoured over lithium aluminium hydride reduction which can lead to low yield and a lack of reproducibility.12 The two-step procedure has previously been used by Kirilyuk et al. for the synthesis of 2,5bis(spirocyclohexane)-substitued nitroxides and in our hands gave 7, reproducibly, at 83% yield.13 Alcohol 7 was then converted to tosylate 8, and the tosyl group was substituted with ammonia, yielding amine 9.14 Efficient amination (80%) was achieved using a 7 N solution of ammonia in methanol. Amine 9 was transformed using a one-step procedure into bromomaleimide 1 in the presence of bromomaleimic anhydride using acetic acid as the solvent.¹⁵ This reaction gave 1 with 47% yield and the nitroxyl group was shown to be unaffected by the reaction conditions, i.e. no reduction was observed by continuous wave (CW) EPR spectroscopy.

When this one-step bromomaleimide formation reaction was attempted on the commercial aminopyrrolidinoxyl radical **10** the formation of a complex mixture was observed. This mixture did not give any signal in CW EPR spectroscopy, suggesting that reduction of the nitroxyl moiety had occurred. Thus, **3** was synthesized from amine **10**, using a two-step reaction pathway (Scheme 3).¹⁶ This procedure consists of the synthesis of a mixture of compounds **11** and **11'**, using bromomaleic anhydride, followed by an intramolecular cyclisation giving compound **3** with an overall yield of 56%.

In both families of NGM labels, the OPh derivative (2 and 4) was synthesized, with an excellent yield, from the bromo precursor (6 and 10 respectively) using phenol in the presence of t-BuOK.¹⁰



Figure 3 X-band CW EPR spectra at room temperature (Bruker EMX with SHQ resonator) for the labels **2** (longer linker, black) and **4** (shorter linker, red) after addition to Sperm Whale Myoglobin S3C and measured in PBS buffer with 50% glycerol. Data have been overlaid at the central y = 0 point to correct for small differences in microwave frequency and have been normalised by their maximum intensity. Spectra were taken under non-saturating conditions at room temperature with a modulation amplitude of 0.8 G per point.

Continuous wave (CW) EPR spectroscopy of the compounds did not demonstrate any decrease in radical content over the course of the reactions. The structure of the compounds was confirmed through NMR spectroscopy, mass spectrometry and X-ray crystallography. The crystallographic structures are presented in Figure 1. The crystals were racemic and diffracted well to give single independent results for **1**, **2** and **4**. Crystals of **3** gave less clear results. However, HPLC, TLC and NMR results for **3** did not indicate that it was less pure than the other end products.

To demonstrate that the labels bind to proteins through loss of either their bromo or O-Phenyl groups, and to see if there were any clear differences in mobility between the families, 1 - 4 were added to Sperm Whale Myoglobin. This was an available protein containing one cysteine residue for labeling at position 3, which is a serine in the wild type.¹⁷ A 10 times excess of spin label was incubated with the protein for 1 hour at room temperature or at 4°C overnight. Size exclusion chromatography was then employed to remove unreacted label. LC-MS confirmed that all four labels bound to myoglobin and gave the expected mass increase, with no free protein observed (Figure 2). The CW EPR spectra for these samples show that the labels have a reduced mobility compared to the free labels which gave a characteristic sharp three-line spectrum. The broader spectra

for the shorter linked spin labels, **3** and **4**, demonstrate that they have a further reduced conformational freedom compared to the longer linkers of **1** and **2**, see figure 3.^{9,18}

In conclusion, four new nitroxide-containing spin labels have been synthesized with next generation maleimide functionalities. This may lead to the ability to selectively bind the spin label to vicinal cysteines and trials are ongoing.

Acknowledgment

This work was funded by EPSRC, Grant Number EP/L022044/1, a Royal Society University Research Fellowship to JEL, Royal Society Research Grant RG120645 and support from Active Spectrum Inc and the Wellcome Trust-JIF funding scheme [grant number 063597] which funded the purchase of the Waters 2795 HPLC and LCT mass spectrometer at the BSRC Mass Spectrometry and Proteomics Facility, University of St Andrews. We acknowledge the use of the ESRC UK National Mass Spectrometry Facility at Swansea University and the MS and NMR services in the EaStCHEM School of Chemistry, St Andrews. We thank Prof. Jason Chin (LMB, Cambridge, UK) for myoglobin plasmid and Prof David O'Hagan for laboratory space in the EaStCHEM School of Chemistry, St Andrews.

Supporting Information

Yes

Primary Data

The magnetic resonance data supporting this publication can be accessed at <u>http://dx.doi.org/10.17630/19ac1929-f829-449b-adee-323baeedf0e5</u>. CCDC 1468783-1468786 contains the supplementary crystallographic data for this paper. The data can be obtained free of charge from The Cambridge Crystallographic Data Centre via <u>www.ccdc.cam.ac.uk/structures</u>. The primary data for the LC-MS analysis have been deposited to the ProteomeXchange Consortium via the PRIDE partner repository with the dataset identifier PXD003824.¹⁹

References and Notes

- (1) New address: PharmaCytics Operations BV, Novio Tech Campus, Office 3.12, Transistorweg 5v, 6534 AT Nijmegen, NL.
- (2) New address: Almac Group, 5 Fleming Building, Edinburgh Technopole, Milton Bridge, EH26 0BE, UK.
- (3) Hubbell, W. L.; López, C. J.; Altenbach, C; Yang, Z. Curr. Op. Struct. Biol. 2013, 23, 725.
- (4) Clore, G. M.; Iwahara, J. Chem. Rev. 2009, 109, 4108.
- (5) (a) Esmann, M.; Sar, P. C.; Hideg, K.; Marsh, D. Analytical Biochem. **1993**, *213*, 336. (b) Fawzi, N. L.; Fleissner, M. R.; Anthis, N. J.; Kálai, T.; Hideg, K.; Hubbell, W. L.; Clore, G. M. J. Biomol. NMR **2011**, *51*, 105.
- (6) Fiser, A.; Simon, I. Meth. Enzymol. 2002, 325, 10.
- (7) (a) Liu, C. C.; Schultz, P. G. Annu. Rev. Biochem. 2010, 79, 413. (b)
 Schmidt, M. J.; Borbas, J.; Drescher, M.; Summerer, D. J. Am. Chem. Soc., 2014, 136, 1238.
- (8) Smith, M. E. B.; Schumacher, F. F.; Ryan, C. P.; Tedaldi, L. M.; Papaioannou, D.; Waksman, G.; Caddick, S.; Baker, J. R. *J. Am. Chem. Soc.* **2010**, *132*, 1960
- (9) Schumacher, F. F.; Sanchania,V. A.; Tolder, B.; Wright, Z. V. F.; Ryan, C. P.; Smith, M. E. B.; Ward, J. M.; Caddick, S.; Kay, C. W. M.; Aeppli, G.; Chester, K. A.; Baker, J. R. *Scientific Reports*, **2013**, *3*, 1525.
- (10) Marculescu, C.; Kossen, H.; Morgan, R. E.; Mayer, P.; Fletcher, S. A.; Tolner, B.; Chester, K. A.; Jones, L. H.; Baker, J. R. *ChemComm*, **2014**, *50*, 7139.
- (11) Rozantsev, E.G., Free Nitroxyl Radicals; Plenum Press:New York 1970, 203.
- (12) Grimaldi, M.; Scrima M.; Esposito, C.; Vitiello, G.; Ramunno, A.; Limongelli, V.; D'Errico, G.; Novellino, E.; D'Ursi, A. M., *Biochimica et Biophysica Acta*, **2010**, *1798*, 660

- (13) Kirilyuk, I. A.; Polienko, Y. F.; Krumkacheva, O. A.; Strizhakov, R. K.; Gatilov, Y. V.; Grigor'ev, I. A.; Bagryanskaya, E. G., *J. Org. Chem.*, **2012**, *77*, 8016.
- (14) Drăguțan, I.; Drăguțan, V.; Melhorn R. J., Bull. Soc. Chim. Belg., 1988, 97, 457.
- (15) Martinez-Ariza, G.; Dietrich, J.; De Moliner, F.; Hulme, C., *SYNLETT.*, **2013**, *24*, 1801.
- (16) Dreyer, J. L.; Beinert, H.; Keana, J. F.; Hankovszky, O. H.; Hideg, K.; Eaton, S. S.; Eaton, G. R. *Biochimica et Biophysica Acta*, **1983**, 745, 229.
- (17) Motion, C. L.; Lovett, J. E.; Bell, S.; Cassidy, S. L.; Cruikshank, P. A. S.; Bolton, D. R.; Hunter, R. I.; El Mkami, H.; Van Doorslaer, S.; Smith, G. M., J. Phys. Chem. Lett., **2016**, 7, 1411.
- (18) Stone, T. J.; Buckman, T.; Nordio, P. L.; McConnell, H. M. Proc. Natl. Acad. Sci., 1965, 54, 1010.
- (19) Vizcaíno, J. A.; Csordas, A.; del-Toro, N.; Dianes, J. A.; Griss, J.; Lavidas, I.; Mayer, G.; Perez-Riverol, Y.; Reisinger, F.; Ternent, T.; Xu, Q. W.; Wang, R.; Hermjakob, H. *Nucleic Acids Res.*, **2016**, *44(D1)*, 447.
- (20) Hideg, K.; Hankovszky, H. O.; Lex, L.; Kulcsár, Gy. Synthesis, 1980, 911.
- (21) Powell, J. H.; Johnson II, E. M.; Gannett, P. M. *Molecules*, **2000**, *5*, 1244.
- (22) Lee, T. D.; Keana, J. F. W. J. Org. Chem, **1975**, 40, 3145.
- (23) **3-[[(Ethoxycarbonyl)oxy]carbonyl]-2,5-dihydro-2,2,5,5tetramethyl-1H-pyrrol-1-yloxy (6)** Ethylchloroformate (2.9 g; 26.7 mmol) was added dropwise to a stirred cold (-10 °C) solution of **5** (3.6 g; 19.5 mmol) in a mixture of dry toluene (155.0 mL) and triethylamine (3.5 mL; 35.5 mmol). After stirring for 50 minutes, the solvent was evaporated and the residue was triturated with ether. The precipitate was filtered off, washed with ether. The organic layer was concentrated *in vacuo* and the residue was recrystallized from hexane yielding **6** (5.0 g; quantitative) as a yellow solid. HRMS ESI (*m/z*) calcd for $C_{12}H_{18}NO_5^+$, 256.1179 found 256.1176.

3-Hydroxymethyl-2,2,5,5-tetramethylpyrroline-*N***-oxyl (7)** A solution of NaBH₄ (1.5 g; 39.0 mmol) in ethanol was cooled down with an ice bath and 6 (5.0 g; 19.5 mmol) was added portion wise upon stirring. After stirring for 2 h, the solvent was evaporated under reduce pressure and the residue was diluted with water and extracted with ether. The extract was dried and concentrated to give 7 (2.8 g; 85%) as a yellow powder. ¹H NMR (400 MHz, acetone d₆/D₂O + 1.5 eq. Na₂S₂O₄) δ 1.14 (s, 6H), 1.16 (s, 6H), 4.02 (d, *J* = 1.7 Hz, 2H), 5.50 (s, 1H);^{20,21} HRMS ESI (*m*/*z*) calcd for C₉H₁₆NO₂Na⁺, 193.1073 found 193.1070.

2,5-Dihydro-2,2,5,5-tetramethyl-3-[[[(4-

methylphenyl}sulfonyl]oxy]methyl]-1H-pyrrol-1-yloxy (8) A solution of **7** (2.5 g; 14.5 mmol) and trimethylamine (1.9 mL; 19.3 mmol) in dry dichloromethane (40.0 mL) was cooled at -10°C, and then tosyl chloride (2.8 g; 14.5 mmol) was added portion wise upon vigorous stirring. The solution was stirred for 3 h at rt, washed with water and with a sat. solution of NaHCO₃, dried and concentrated under *vacuo*. The crude was purified by column chromatography (cyclohexane/EtOAc) yielding **8** (3.5 g; 66%) as a yellow solid. HRMS ESI (*m/z*) calcd for C₁₆H₂₂O₄NNaS⁺, 347.1162 found 347.1154.

3-(Aminomethyl)-2,5-dihydro-2,2,5,5-tetramethyl-1H-

pyrrol-1-yloxy (9) A solution of **8** (1.5 g; 4.6 mmol) in anhydrous methanol was added dropwise into ammonia solution (75.0 mL; 7 N in MeOH). The mixture was stirred for 2 h at rt, then left to stand overnight. The solvent was evaporated under reduced pressure. The residue was treated with a buffer solution (60.0 mL; mixture of citric acid and Na₂HPO₄) at pH 5 and extracted with ether. The aqueous layer was saturated with sodium hydroxide and extracted with ether. The extract was dried and concentrated yielding **9** (706.0 mg; 90 %) as an orange oil. ¹H NMR (400 MHz, CDCl₃ + phenylhydrazine to reduce the nitroxide radical to a diamagnetic N-hydroxylamine,²² since we found that our product was degraded by Na₂S₂O₄) δ 1.24 (s, 6H), 1.25 (s, 6H),

3.31 (d, J = 1.8 Hz, 2H), 5.42 (s, 1H); HRMS ESI (m/z) calcd for C₉H₁₈ON₂⁺, 170.1414 found 170.1408.

3-((3-bromo-2,5-dihydro-1*H*-pyrrole-2,5-dione-1-yl)methyl)-2,5-dihydro-2,2,5,5-tetramethyl-1*H*-pyrrol-1-yloxy (1)

Bromomaleic anhydride (388.2 µL; 4.2 mmol) was dissolved in acetic acid (7.0 mL). Nitroxyl **9** (707.9 mg; 4.2 mmol) in acetic acid (7.0 mL) was added, and the reaction was heated at 80°C for 3 h. The solvent was removed under *vacuo* and the mixture was purified by column chromatography (cyclohexane/EtOAc) to give the bromomaleimides **1** (644.7 mg; 47%) as an orange powder. ¹H NMR (400 MHz, CDCl₃ + phenylhydrazine) δ 1.38 (s, 6H), 1.45 (s, 6H), 4.17 (d, *J* = 1.4 Hz; 2H), 5.40 (s, 1H) , 6.94 (s, 1H); HRMS NSI (*m/z*) calcd for C₁₃H₁₇O₃N₂Br⁺, 328.0417 found 328.0417; mp = 146-147°C.

3-(3-Bromo-2,5-dihydro-1*H*-pyrrole-2,5-dione-1-yl)-2,5dihydro-2,2,5,5-tetramethyl-1*H*-pyrrol-1-yloxy (3)

To a stirred solution of amine **10** (489.0 mg; 3.1 mmol) in dry ether (24.7 mL) bromomaleic anhydride (286.7 μ L; 3.1 mmol) was added. The reaction was left stirring at rt for 3 h. The precipitate was filtered and washed with ether yielding a mixture of **11** and **11'** (910.0 mg; 87%) as a yellow solid.

The mixture of **11** and **11'** (910 mg; 2.7 mmol) and sodium acetate (222.2 mg; 2.7 mmol) were dissolved in acetic anhydride (13.5 mL) and heated at 60-70°C for 3 h. The reaction mixture was then concentrated, dissolved in DCM and filtered. The filtrate was concentrated and purified by column chromatography (cyclohexane/EtOAc) to give **3** (853 mg; 64%) as an orange solid. ¹H NMR (400 MHz, CDCl₃ + phenylhydrazine) δ 1.08 (s, 3H), 1.25 (s, 3H), 1.26 (s, 3H), 1.36 (s, 3H) 1.82 (dd, *J* = 12.5, 8.8 Hz; 1H), 2.93 (dd, *J* = 12.5, 11.0 Hz, 1H), 4.47 (dd, *J* = 11.0, 8.8 Hz, 1H), 6.89 (s, 1H); HRMS ESI (*m*/*z*) calcd for C₁₂H₁₆O₃N₂BrNa⁺, 338.0237 found 338.0223; mp = 101-102°C.

Phenoxymaleimide 2 and 4; General procedure

To molten phenol (13.2 mmol), potassium *tert*-butoxide (1.1 mmol) in dry dioxane (0.8 mL) was added dropwise and the solution was left stirring for 10 min at 40 °C. Then a solution of bromomaleimide **1** or **3** (0.8 mmol) in dry dioxane (0.8 mL) was added dropwise and the resulting mixture was stirred at 40 °C for 30 minutes. After this time, the solvent was evaporated under reduced pressure. The mixture was purified by column chromatography (cyclohexane/EtOAc) to give the corresponding phenoxymaleimide.

3-((3-phenoxy-2,5-dihydro-1*H*-pyrrole-2,5-dione-1yl)methyl)-2,5-dihydro-2,2,5,5-tetramethyl-1*H*-pyrrol-1-

yloxy (2) yield: 279 mg (92%); Aspect: light yellow powder; ¹H NMR (400MHz, CDCl₃ + phenylhydrazine) δ 1.32 (s, 6H), 1.40 (s, 6H), 4.14 (d, *J* = 1.4 Hz; 2H), 5.34 (s, 1H), 5.48 (s, 1H), 7.36-7.29 (m, 2H), 7.51-7.43 (m, 3H); HRMS NSI (*m*/*z*) calcd for $C_{19}H_{22}O_4N_2^+$, 342.1574 found 342.1570; mp = 92-94°C.

3-(3-Phenoxy-2,5-dihydro-1*H***-pyrrole-2,5-dione-1-yl)-2,5dihydro-2,2,5,5-tetramethyl-1***H***-pyrrol-1-yloxy (4) yield: 345 mg (92%), Aspect: yellow solid, ¹H NMR (400MHz, CDCl₃ +** phenylhydrazine) δ 1.13 (s, 3H), 1.24 (s, 3H), 1.27 (s, 3H), 1.36 (s, 3H), 1.80 (dd, *J* = 12.4, 8.7 Hz, 1H), 2.98 (dd, *J* = 11.2, 12.4 Hz, 1H), 4.46 (dd, *J* = 11.2, 8.7 Hz, 1H), 5.29 (s, 1H), 7.37-7.30 (m, 2H), 7.54-7.43 (m, 3H); HRMS ESI (*m*/*z*) calcd for C₁₈H₂₁N₂O₄Na⁺, 352.1394 found 352.1371; mp = 120-122°C.